Baxter's blood disorder drug gets FDA approval

(Reuters) - (This Oct. 24 story has been corrected to remove paragraph saying that Obizur will compete with Biogen Idec Inc's BIIB.O Eloctate. Eloctate is approved to treat congenital hemophilia A, not acquired hemophilia A) Drugmaker Baxter International Inc said the U.S. Food and Drug Administration had approved its drug for treating bleeding episodes in adults with a rare bleeding disorder. The drug, Obizur, has been approved for use in patients with acquired hemophilia A, which usually affects older adults, Baxter said in a statement. ...



via Health News Headlines - Yahoo News http://ift.tt/1tykPDH